Overall, out of 304 participants, 282 (92.8%) concluded the trial by attending the end-of-trial safety evaluation, 272 (89.5%) underwent body weight assessment at the week 104 end-of-treatment visit to determine the long term effects of semaglutide, and 243 (79.9%) adhered to the treatment protocol until the end-of-treatment visit (Fig
Lactobacillus reuteri ZJ617 maintains intestinal integrity via regulating tight junction, autophagy and apoptosis in mice challenged with lipopolysaccharide
Recent clinical research has identified several key findings about Ozempic and sexual function: Non-diabetic men prescribed semaglutide (Wegovy may be prescribed for weight management) showed a higher likelihood of developing erectile dysfunction compared to control groups (0.4% vs control group) [7] The overall rate of erectile dysfunction remains relatively low at 1.5% Some users report increased libido after weight loss and improved sexual arousal [8] The medication's effects on sexual function appear to work through multiple pathways
Most thyroid specialists see no contraindication to combining these medications when doses are timed properly
Those who took GLP-1s for less than 18 months before discontinuing saw no significant risk reduction compared to the group on sulfonylureas at the end of the trial
For TTY users: Use your preferred relay service or dial 711 then 988